» Articles » PMID: 35295749

Provision and Standards of Care for Treatment and Follow-up of Patients with Autoimmune Hepatitis (AIH)

Abstract

Background: Autoimmune hepatitis (AIH) is a substantial UK health burden, but there is variation in care, facilities and in opinion regarding management. We conducted an audit of service provision and care of patients with AIH in 28 UK hospitals.

Methods: Centres provided information about staffing, infrastructure and patient management (measured against predefined guideline-based standards) via a web-based data collection tool.

Results: Hospitals (14 university hospitals (UHs), 14 district general hospitals (DGHs)) had median (range) of 8 (3-23) gastroenterologists; including 3 (0-10) hepatologists. Eight hospitals (29%, all DGHs) had no hepatologist. In individual hospital departments, there were 50% (18-100) of all consultants managing AIH: in DGH's 92% (20-100) vs 46% (17-100) in UHs. Specialist nurses managed AIH in only 18%. Seventeen (61%) hospitals had a histopathologist with a liver interest, these were more likely to find rosettes than those without (172/795 vs 50/368; p<0.001).Of 999 steroid-treated patients with ≥12 months follow-up, 25% received steroids for <12 months. After 1 year of treatment, 82% of patients achieved normal serum alanine aminotransaminase (ALT); this was higher in UHs than DGHs. Three-monthly liver blood tests were inadequately recorded in 26%. Of potentially eligible patients with liver decompensation, transplantation was apparently not considered in 5% (n=7). The same standards were attained in different types of hospital.

Conclusion: Management of AIH in UK hospitals is often shared between most gastroenterologists. Blood test monitoring and treatment duration are not always in line with recommendations. Some eligible patients with decompensation are not discussed with transplant teams. Care might be improved by expanding specialist input and management by fewer designated consultants.

Citing Articles

Provision and standards of care for treatment and follow-up of patients with auto-immune hepatitis (AIH).

Chapman R Frontline Gastroenterol. 2022; 13(2):96-97.

PMID: 35300466 PMC: 8862494. DOI: 10.1136/flgastro-2021-101928.

References
1.
Gordon V, Adhikary R, Appleby V, Das D, Day J, Delahooke T . Diagnosis, presentation and initial severity of Autoimmune Hepatitis (AIH) in patients attending 28 hospitals in the UK. Liver Int. 2018; 38(9):1686-1695. DOI: 10.1111/liv.13724. View

2.
Dhaliwal H, Hoeroldt B, Dube A, McFarlane E, Underwood J, Karajeh M . Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis. Am J Gastroenterol. 2015; 110(7):993-9. DOI: 10.1038/ajg.2015.139. View

3.
Williams R, Aithal G, Alexander G, Allison M, Armstrong I, Aspinall R . Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK. Lancet. 2019; 395(10219):226-239. DOI: 10.1016/S0140-6736(19)32908-3. View

4.
Wong L, Fisher H, Stocken D, Rice S, Khanna A, Heneghan M . The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology. 2018; 68(4):1487-1497. PMC: 6585808. DOI: 10.1002/hep.30031. View

5.
Pape S, Gevers T, Belias M, Mustafajev I, Vrolijk J, van Hoek B . Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2019; 17(10):2068-2075.e2. DOI: 10.1016/j.cgh.2018.12.035. View